NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A

Swedish Orphan Biovitrum AB Sweden

XTEND-Kids is the first assessment of once-weekly ALTUVOCT® prophylaxis in previously treated childrenResults indicate highly effective bleed protection in children under 12 years of age with severe haemophilia AView original content:https://www.prnewswire.co.uk/news-releases/nejm-publishes-altuvoct-phase-3-xtend-kids-results-highlighting-treatment-potential-for-children-with-severe-haemophilia-a-302200371.html